Status:
RECRUITING
Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Lead Sponsor:
University of Pisa
Collaborating Sponsors:
IRCCS Burlo Garofolo
Conditions:
Herpesviridae Infections
Herpes Simplex 1
Eligibility:
All Genders
6-18 years
Brief Summary
* Herpesvirus infections may be severe in immunocompromised patients, with a high risk of complications and mortality. * Recipients of hematopoietic stem cell transplant (HSCT) or patients receiving h...
Detailed Description
Herpesvirus infections may lead to severe disease with a high risk of complications and mortality in hematopoietic stem cell transplant (HSCT) recipients, or in patients receiving high-intensity chemo...
Eligibility Criteria
Inclusion
- Patients with Hematological malignancies
- HSCT recipients who require ACV prophylaxis or treatment for HSV-VZV infection or
- Children undergoing high-intensity antineoplastic chemotherapy who need ACV treatment.
- Intravenous or oral ACV dosing
- Active/available a therapeutic drug monitoring (TDM) protocol for ACV
- Informed consent signed by patient's parents
Exclusion
- lack of signed informed consent
- lack of TDM for ACV
- unavailable patient's demographic characteristics
Key Trial Info
Start Date :
September 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05198570
Start Date
September 15 2021
End Date
March 31 2026
Last Update
June 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS Burlo Garofolo, Bone Marrow Transplant Unit, Institute for Maternal and Child Health
Trieste, TS, Italy, 34137